| Literature DB >> 24349118 |
Carlos A Rossetti1, Kenneth L Drake2, Prasad Siddavatam2, Sara D Lawhon1, Jairo E S Nunes1, Tamara Gull1, Sangeeta Khare1, Robin E Everts3, Harris A Lewin3, Leslie Garry Adams1.
Abstract
Brucella melitensis causes the most severe and acute symptoms of all Brucella species in human beings and infects hosts primarily through the oral route. The epithelium covering domed villi of jejunal-ileal Peyer's patches is an important site of entry for several pathogens, including Brucella. Here, we use the calf ligated ileal loop model to study temporal in vivo Brucella-infected host molecular and morphological responses. Our results document Brucella bacteremia occurring within 30 min after intraluminal inoculation of the ileum without histopathologic traces of lesions. Based on a system biology Dynamic Bayesian Network modeling approach (DBN) of microarray data, a very early transient perturbation of the host enteric transcriptome was associated with the initial host response to Brucella contact that is rapidly averted allowing invasion and dissemination. A detailed analysis revealed active expression of Syndecan 2, Integrin alpha L and Integrin beta 2 genes, which may favor initial Brucella adhesion. Also, two intestinal barrier-related pathways (Tight Junction and Trefoil Factors Initiated Mucosal Healing) were significantly repressed in the early stage of infection, suggesting subversion of mucosal epithelial barrier function to facilitate Brucella transepithelial migration. Simultaneously, the strong activation of the innate immune response pathways would suggest that the host mounts an appropriate protective immune response; however, the expression of the two key genes that encode innate immunity anti-Brucella cytokines such as TNF-α and IL12p40 were not significantly changed throughout the study. Furthermore, the defective expression of Toll-Like Receptor Signaling pathways may partially explain the lack of proinflammatory cytokine production and consequently the absence of morphologically detectable inflammation at the site of infection. Cumulatively, our results indicate that the in vivo pathogenesis of the early infectious process of Brucella is primarily accomplished by compromising the mucosal immune barrier and subverting critical immune response mechanisms.Entities:
Mesh:
Year: 2013 PMID: 24349118 PMCID: PMC3857238 DOI: 10.1371/journal.pone.0081719
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primers for Real Time – PCR Analysis of Genes in B. melitensis-Infected Bovine Peyer's Patch.
| GENEBANK ACCESSION # | GENE SYMBOL | GENE NAME | FORWARD PRIMERS (5′-3′) | REVERSE PRIMERS (5′-3′) |
| NM_173895 |
| Bactericidal/permeability-increasing protein |
|
|
| NM_175793 |
| Mitochondrial-activated protein kinase 1 |
|
|
| NM_174006 |
| Chemokine (C-C motif) ligand 2 |
|
|
| NM_173925 |
| Interleukin 8 |
|
|
| NM_001033608 |
| Macrophage migration inhibitory factor |
|
|
| NM_001034034 |
| Glyceraldehyde-3-phosphate dehydrogenase |
|
|
Figure 1Kinetics of Peyer's Patch Infection with B. melitensis 16 M.
Jejunal-ileal loops were intraluminally inoculated in 3 ml containing 1×109 CFU of B. melitensis 16 M/ml. Tissue (Peyer's patch) samples of 0.1 g of mucosal tissue were extracted at 0.25, 0.5, 1, 2, 4, 8 and 12 h from every infected loop, intensively washed 3 times in PBS, macerated and diluted in 1 ml of distilled water. To evaluate the kinetics of the infection, macerated samples were serially diluted and cultured on Farrell's medium. Numbers of CFU recovered from bovine Peyer's patches are the average of 4 calves. Bars represent standard deviation.
Figure 2Graphic Representation of Bovine Genes Differentially Expressed throughout the Experiment.
(DE = differentially expressed). Solid bars represent genes up-regulated; open bars represent genes down-regulated.
Figure 3Graphic Representation of Number of Pathways and GO Terms Differentially Expressed at each time point from 15 min to 4 h p.i.
Squares = GO Biological processes; Squares with X = GO Molecular functions; Triangle = Cellular components; Diamond = Pathways.
Bayesian z-score of 56 Pathways in Eight categories post- B. melitensis Infection Compared to Controls.
| Name | Description | Category | 0.25 h | 0.5 h | 1 h | 2 h | 4 h |
| hsa04510 |
| CC | 4.48 | 3.68 | 4.3 | 4.35 | 2.31 |
| hsa04520 | Adherens junction | CC | 4.06 | −3.13 | 4.01 | 3.84 | 1.84 |
| hsa04530 |
| CC | −4.35 | −3.68 | −4.74 | 4.27 | 2.23 |
| hsa04540 |
| CC | 3.74 | 2.88 | 3.05 | 3.12 | 2.18 |
| hsa04110 |
| CGD | 4.18 | 3.05 | 3.86 | 3.19 | −2.21 |
| hsa04210 |
| CGD | 4.72 | 3.44 | 4.25 | 3.42 | 2.02 |
| hsa04810 |
| CM | 4.51 | 3.43 | 4.4 | 4.16 | 2.55 |
| hsa04610 | Complement and coagulation cascades | IS | 4.85 | −3.23 | 4.56 | −2.39 | 2.28 |
| hsa04612 |
| IS | 4.72 | 3.15 | 3.69 | 3.67 | 2.27 |
| hsa04620 |
| IS | 4.48 | 3.55 | 4.28 | 3.13 | 2.29 |
| hsa04640 |
| IS | 4.11 | 3.1 | 3.87 | 3.38 | 2.07 |
| hsa04650 |
| IS | 3.71 | 3.36 | 5.13 | 3.5 | 1.9 |
| hsa04660 |
| IS | 4.66 | 3.82 | 4.61 | 3.6 | 2.2 |
| hsa04662 |
| IS | 4.13 | 3.63 | 4.72 | 3.55 | 2.98 |
| hsa04664 |
| IS | 4.56 | 3.75 | 4.56 | 4.08 | 2.53 |
| hsa04670 |
| IS | 4.65 | 3.77 | 4.73 | 3.91 | 2.58 |
| hsa99103 | Apoptotic DNA fragmentation and homeostasis pathway | IS | −1.72 | −2.16 | −2.17 | −1.83 | −2.18 |
| hsa99104 |
| IS | 4.52 | 3.47 | 4.41 | 3.01 | 1.98 |
| hsa99105 | BRC signaling pathway | IS | 3.8 | −2.48 | 3.72 | 2.19 | −1.47 |
| hsa99106 | B Cell Receptor Complex pathway | IS | 2.39 | 4.05 | 4.56 | 0.95 | 2.9 |
| hsa94660 |
| ID | 4.71 | 4.17 | 4.94 | 3.73 | 2.15 |
| hsa00626 | Nitrobenzene degradation | ID | 4.11 | 2.21 | 4.86 | 2.7 | 1.69 |
| hsa00940 |
| ID | 4.13 | 4 | 4.28 | 3.07 | 1.8 |
| hsa01430 |
| ID | 4.92 | 4.19 | 5.77 | 4.16 | 2.82 |
| hsa05110 |
| ID | 2.98 | 2.42 | 3.22 | 2.67 | 2.26 |
| hsa05120 |
| ID | 4.47 | 3.79 | 3.69 | 4.35 | 2.58 |
| hsa05130 |
| ID | −3.77 | −2.77 | −3.12 | −2.7 | −2.03 |
| hsa99020 |
| ID | 5.39 | 3.48 | 3.87 | −2.06 | 1.27 |
| hsa99100 | Activation of Csk through the T-Cell Receptor pathway | ID | 3.29 | 1.51 | 2.45 | 1.75 | 0.91 |
| hsa99101 | Activation of cAMP-dependent protein kinase PKA pathway | ID | 2.47 | −1.03 | 1.22 | 2.29 | 1.79 |
| hsa99102 | Anthrax Toxin Mechanism of Action pathway | ID | 2.85 | 1.39 | 3.15 | 3.87 | 0.99 |
| hsa99107 |
| ID | 3.51 | 3.06 | 5.2 | 3.57 | −2.01 |
| hsa99108 | Blockade Neurotransmitter Release by Botulinum Toxin path | ID | −0.96 | 0 | 0 | 0.63 | 0 |
| hsa99109 | CCR3 signaling in Eosinophils pathway | ID | 4.78 | −2.89 | 5.06 | −4.63 | 3.29 |
| hsa99110 | CD40L Signaling Pathway | ID | 5.71 | 4.32 | 3.64 | −4.24 | 3.28 |
| hsa99111 | Calcium Signaling by HBx of Hepatitis B virus pathway | ID | −1.23 | −0.97 | −2.21 | −0.1 | 0 |
| hsa99112 | Cytokine Inflammatory Response | ID | 5.43 | 3.58 | 3.84 | −2.49 | 2.08 |
| hsa99113 | Trefoil Factors Initiate Mucosal Healing | ID | −4.46 | −3.07 | 4.37 | 3.56 | −2.57 |
| hsa99114 |
| ID | 4.39 | 3.61 | 3.91 | 3.15 | 2.35 |
| hsa02010 |
| MT | 3.74 | 3.72 | 4.55 | 3.7 | 2.18 |
| hsa04010 |
| ST | 4.75 | 3.63 | 4.17 | 3.89 | 2.43 |
| hsa04012 |
| ST | 4.39 | 3.66 | 4.61 | 4.53 | 2.47 |
| hsa04020 |
| ST | 4.97 | 3.59 | 4.86 | 3.68 | 2.37 |
| hsa04070 |
| ST | −4.62 | −3.35 | −4.21 | −4.3 | 2.18 |
| hsa04150 |
| ST | 3.55 | 3.46 | 5.24 | 4.01 | 2.45 |
| hsa04310 |
| ST | 4.85 | 4.15 | 4.73 | 4.41 | 1.93 |
| hsa04330 | Notch signaling pathway | ST | −4.43 | 3.61 | 3.56 | 4.11 | 2.6 |
| hsa04340 |
| ST | 4.66 | 3.49 | 3.55 | 3.52 | 1.27 |
| hsa04350 | TGF-beta signaling pathway | ST | 4.47 | −2.88 | −3.65 | 4.02 | 1.96 |
| hsa04370 |
| ST | 4.75 | 4.24 | 5.11 | 3.82 | 2.68 |
| hsa04630 |
| ST | 4.43 | 3.76 | 4.93 | 3.37 | 2.39 |
| hsa04060 | Cytokine-cytokine receptor interaction | SM | 4.34 | 3.38 | 4.12 | −3.06 | 2.04 |
| hsa04080 |
| SM | 4.44 | 3.62 | 4.17 | 3.31 | 2.02 |
| hsa04512 |
| SM | 5.03 | 3.55 | 4.07 | 3.47 | 2.52 |
| hsa04514 |
| SM | 4.55 | 3.95 | 4.64 | 3.48 | 2.31 |
Categories - CC = cell communication; CGD = cell growth and death; CM = cell motility; IS = immune system; ID = infectious disease; MT = membrane transport; ST = signal transduction; SM = signaling molecule measured time points 15, 30, 60, 120, and 240 minutes p.i. The Bayeian z-scores represent the degree of perturbation of the group of pathway genes versus the controls. Positive z-scores represent activation of the pathway (pathway score is dominated by more up-regulated genes), while the negative z-score represents pathway repression (pathway score is dominated by down-regulated genes). Bolded pathways represent pathways highly perturbed at earlier time points (either activated or repressed) with decreased differential expression at later time points to near or non-statistical differences in comparison with control tissues.
Figure 4Heatmap of Significantly Perturbed Pathways Scores in Bovine Peyer's Patch Infected with B. melitensis.
Thirty-seven pathways were identified as significantly perturbed (97.5% confidence) from the early stage of infection (15–60 m.p.i.). The darker red gradients indicate higher Bayesian activation scores (more up-regulated gene expression within the pathway) while the darker green gradients indicate more repressed pathway activity (more down-regulated gene expression).
Figure 5Pathway Score Heat Map for Cell Communication Related Pathways.
This heat map shows the repressed state of activity for the Tight Junction (TJ) and Trefoil Factors (TF) pathway in comparison to the Gap Junction, Integrin-mediated Cell Adhesion and Cell Adhesion Molecules pathways. Note that the TJ and TF pathways have a complex activation pattern. The TJ is tri-phasic in that it is highly repressed in the early stage, becomes moderately activated at 60 and 120 min p.i, and then becomes repressed at 240 min p.i. The TF pathway is bi-phasic in that it is highly repressed in the early stage but becomes moderately activated at 120 and 240 min p.i. The darker red gradients indicate higher Bayesian activation scores (more up-regulated gene expression within the pathway) while the darker green gradients indicate more repressed pathway activity (more down-regulated gene expression).
Figure 6Tight Junction Pathway Bayesian Network Model and Gene Score Heat Map.
(A) Tight Junction pathway Bayesian network representation at 30 min post-inoculation. Gene nodes with orange circles on the network are those defined as mechanistic genes that surpass a threshold Bayesian z-score| >2.24|. The network shows gene nodes with gradient colors representing the level of expression (deeper red for higher up-regulated genes and deeper green for down-regulated). (B) The Bayesian score heat map for the gene expression of Brucella infected host Peyer's patch versus non-infected controls. The heat map is colorized and corresponds to the gene node expression levels. Grey color represents little to no expression difference between Brucella-infected and control loops. The heat map columns are by time post-infection in minutes.
Figure 7Toll-like Receptor Related Gene Score Heat Map by Time Point Post-Inoculation.
The heat map shows a number of up-regulated genes occurring in the early stage (15–60 minutes post-inoculation) as indicated by the darker red boxes as well as down-regulated genes as indicated by the darker green boxes.
Genes Significantly Expressed in the TLRS Pathway (z-score |2.24|).
| Symbol | Description | 0.25 | 0.5 | 1 h | 2 h | 4 h |
| MAP3K7IP1 | mitogen-activated protein kinase kinase kinase 7 interacting protein 1 | 3.15 | 4.67 | 5.83 | 5.27 | 1.28 |
| NFKB2 | nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) | 3.46 | 3.92 | 5.44 | 3.83 | 3.04 |
| MAPK12 | mitogen-activated protein kinase 12 | 3.6 | 4.28 | 3.78 | 4.67 | 5.32 |
| PIK3CB | phosphoinositide-3-kinase, catalytic, beta polypeptide | 1.96 | 2.6 | 4.86 | 1.81 | 1.89 |
| MAP3K7IP2 | mitogen-activated protein kinase kinase kinase 7 interacting protein 2 | 3.3 | 1.92 | 4.32 | 3.79 | 2.52 |
| IL12A | interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, | 3.5 | 3 | 2.51 | 0.34 | 1.37 |
| NFKBIA | nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | 3.28 | 2.59 | 0.88 | 0.09 | 0 |
| TLR5 | toll-like receptor 5 | 1.64 | 0 | 3.23 | 0 | −0.21 |
| JUN | jun oncogene | 2.42 | 0 | 0 | 3.22 | 0 |
| TLR2 | toll-like receptor 2 | 3.17 | 1.48 | −2.41 | −0.17 | −0.15 |
| AKT1 | v-akt murine thymoma viral oncogene homolog 1 | 0 | 1.05 | 3.14 | 3.15 | 2.82 |
| MAP2K3 | mitogen-activated protein kinase kinase 3 | 0 | 0.29 | 1.48 | 0.49 | 3.09 |
| MAPK9 | mitogen-activated protein kinase 9 | 3.05 | 1.9 | 3.08 | 2.95 | 2.68 |
| IKBKB | inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta | 2.96 | 2.55 | 0 | 0 | 2.17 |
| IFNAR2 | interferon (alpha, beta and omega) receptor 2 | 2.92 | 1.36 | 2.17 | 0 | 0 |
| IKBKG | inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma | 2.69 | 1.31 | 0.04 | 2.84 | 1.69 |
| TLR3 | toll-like receptor 3 | 1.59 | 2.33 | 2.46 | 2.78 | 0.89 |
| CHUK | conserved helix-loop-helix ubiquitous kinase | 2.77 | −1.12 | −2.21 | −0.02 | 1.54 |
| CXCL11 | chemokine (C-X-C motif) ligand 11 | 1.16 | 1.7 | 2.67 | 0.94 | 0.34 |
| PIK3R2 | phosphoinositide-3-kinase, regulatory subunit 2 (beta) | 1.82 | 0.99 | 2.59 | 2.34 | 1.86 |
| IFNAR1 | interferon (alpha, beta and omega) receptor 1 | −1.79 | −0.31 | 2.26 | 0.68 | 0.32 |
| RAC3 | ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3) | −2.42 | 0 | 0 | −0.34 | −0.91 |
| PIK3R4 | phosphoinositide-3-kinase, regulatory subunit 4 | −2.44 | −2.34 | −2.48 | −2.3 | 0 |
| TICAM2 | toll-like receptor adaptor molecule 2 | −1.79 | −1.05 | −2.05 | −2.55 | 0 |
| IL6 | interleukin 6 (interferon, beta 2) | −2.12 | −2.16 | −2.58 | −0.48 | 0 |
| AKT3 | v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) | −2.88 | −0.93 | 0.97 | 1.76 | 0 |
| STAT1 | signal transducer and activator of transcription 1, 91 kDa | −3.04 | −0.75 | 0 | −0.61 | 0 |
| PIK3C2B | phosphoinositide-3-kinase, class 2, beta polypeptide | −3.5 | −0.98 | −1.27 | −0.99 | 0 |
The table lists significantly perturbed (activated or repressed) genes at any time among the 5 different time points (0.25 h through 4 h p.i.).
Figure 8Chemokine Gene Score Heat Map by Time Point Post-Inoculation.
The heat map shows a number of both up-regulated and down-regulated genes (15–240 minutes post-inoculation). Note that there were large numbers of down-regulated and non-expressed chemokine genes. Red indicates an activated state while green indicates repression and grey is no expression change from control.
Figure 9Interleukin Gene Score Heat Map by Time Point Post Inoculation.
The heat map shows a number of both up-regulated and down-regulated genes (15–240 minutes post-inoculation). The heat map shows that much of the up-regulation is short-lived for many of these genes and reversed expression direction or minimally expressed in later time points. Red indicates an activated state while green indicates repression and grey is no expression change from control.
Significantly Altered Genes (Bayesian z-score |2.24|) in the Cell Molecule Adhesion (CAM) pathway.
| Symbol | Description | 0.25 h | 0.5 h | 1 h | 2 h | 4 h |
| Cd28 | CD28 antigen | 2.12 | 0.69 | −3.13 | 0 | −0.22 |
| CD34 | CD34 molecule | 0 | −1.61 | −2.02 | −2.35 | 0 |
| CD58 | CD58 molecule | −3.47 | −2.7 | −2.81 | −3.13 | 0 |
| CD99 | CD99 molecule | −0.99 | 0.86 | 0.82 | 2.5 | 0 |
| CDH1 | cadherin 1, type 1, E-cadherin (epithelial) | −1.88 | −2.82 | 0 | −1.83 | 0.52 |
| CDH15 | cadherin 15, M-cadherin (myotubule) | 2.42 | 0.66 | −0.59 | 2.99 | 1.63 |
| CDH3 | cadherin 3, type 1, P-cadherin (placental) | 2.85 | 1.75 | 0 | 0 | −0.99 |
| CDH5 | cadherin 5, type 2 (vascular endothelium) | −3.36 | −2.08 | −2.54 | −2.65 | −1.97 |
| CLDN1 | claudin 1 | −2.49 | −1.73 | −2.39 | −1.76 | −1.03 |
| Cldn16 | claudin 16 | 2.42 | 1.46 | 1.05 | 0.28 | 2.09 |
| CLDN3 | claudin 3 | 2.71 | 0 | 0 | 0.42 | 2.27 |
| CLDN4 | claudin 4 | 1.33 | 2.18 | 2.43 | 0.95 | 1.29 |
| CLDN5 | claudin 5 (transmembrane protein deleted in velocardiofacial) | 1.79 | 2.14 | 2.95 | 0 | 1.94 |
| CLDN7 | claudin 7 | 1.16 | −0.65 | −3.48 | −2.05 | 0 |
| CNTN1 | contactin 1 | −2.86 | −1.18 | −1.43 | −0.68 | −0.21 |
| Cntnap2 | contactin associated protein-like 2 | 0.51 | 2.59 | 3.41 | 2.75 | 1.26 |
| VCAN | versican | 2.7 | 3.98 | 5.16 | 4.14 | 2.58 |
| ESAM | endothelial cell adhesion molecule | 2.94 | 4.05 | 1.81 | 1.85 | 2.87 |
| VCAM1 | vascular cell adhesion molecule 1 | −2.33 | −2.02 | −3.27 | −3.89 | −1.26 |
| Pecam1 | platelet/endothelial cell adhesion molecule 1 | 2.87 | 0.8 | −1.18 | −1.76 | −0.64 |
| NCAM1 | neural cell adhesion molecule 1 | −3.03 | 0 | 0 | 1.22 | −0.1 |
| F11R | F11 receptor | −0.74 | −0.92 | −0.3 | −1.37 | 2.42 |
| GLG1 | golgi apparatus protein 1 | 0.51 | 1.04 | 2.22 | 0.54 | 2.72 |
| HLA-A | major histocompatibility complex, class I, A | −3.44 | −2.13 | −2.14 | −2.92 | 0 |
| HLA-DMA | major histocompatibility complex, class II, DM alpha | 1.35 | 3.65 | 2.3 | 0.75 | 0 |
| HLA-DOA | major histocompatibility complex, class II, DO alpha | 2.37 | 0 | 1.95 | 0 | 0.61 |
| HLA-DOB | major histocompatibility complex, class II, DO beta | 0.97 | 0.98 | 2.45 | 0.08 | 1.25 |
| HLA-DRA | major histocompatibility complex, class II, DR alpha | −3.07 | −1.86 | −1.32 | −3.09 | −1.57 |
| ICAM1 | intercellular adhesion molecule 1 | 0.25 | 0 | 2.25 | 0 | 0 |
| ICAM2 | intercellular adhesion molecule 2 | 3.06 | 4.5 | 6.19 | 0.44 | 2.82 |
| ITGA4 | integrin, alpha 4 (antigen CD49D, alpha 4 of VLA-4 receptor) | 2.04 | 2.18 | 3.61 | −0.63 | 0 |
| ITGA8 | integrin, alpha 8 | 0.47 | 1.12 | 3.18 | 0.22 | 0.9 |
| ITGA9 | integrin, alpha 9 | −4.84 | −3.42 | −2.55 | −2.27 | −2.02 |
| ITGAL | integrin, alpha L (antigen CD11A (p180), LFA 1; alpha peptide | 1.74 | 2.73 | 4.28 | 2.81 | 0.81 |
| ITGAV | integrin, alpha V (vitronectin receptor, alpha peptide, CD51) | −2.7 | −2.42 | −0.24 | −1.82 | 0 |
| ITGB2 | integrin, beta 2 (complement component 3 receptor 3 and 4 unit) | 3.13 | 2.8 | 4.15 | 4.04 | 2.34 |
| NRXN3 | neurexin 3 | −2.85 | 0 | −1.88 | 1.53 | −2.39 |
| PTPRM | protein tyrosine phosphatase, receptor type, M | 4.37 | −3.96 | −3.08 | −1.19 | −0.24 |
| PVRL1 | poliovirus receptor-related 1 (herpesvirus entry mediator C) | 1.12 | 1.24 | 1.05 | 2.17 | 2.59 |
| PVRL2 | poliovirus receptor-related 2 (herpesvirus entry mediator B) | 0.84 | 1.87 | 5.18 | 1.33 | 1.19 |
| SDC2 | syndecan 2 | 4.05 | 3.81 | 3.75 | 3.27 | 2.16 |
The table lists significantly perturbed (activated or repressed) genes at any time among the 5 different time points (0.25 h through 4 h p.i.).
Significantly Altered Genes (Bayesian z-score |2.24|) in the Extra-Cellular Membrane (ECM) pathway.
| Symbol | Description | t = 15 | t = 30 | t = 60 | t = 120 | t = 240 |
| Agrn | agrin | −0.89 | −2.48 | 1.26 | 2.28 | 1.83 |
| Cd47 | CD47 antigen (Rh-related antigen, integrin-associated signal transducer) | −3.3 | −3.8 | −4.64 | −1.05 | 0 |
| Chad | chondroadherin | −2.65 | −0.08 | −2.44 | −1.6 | −2.62 |
| Col5a1 | collagen, type V, alpha 1 | 4.03 | 3.59 | 4.81 | 3.31 | 2.5 |
| Col5a2 | collagen, type V, alpha 2 | −2.89 | −1.59 | −1.73 | −2.45 | −1.94 |
| COL6A2 | collagen, type VI, alpha 2 | 0.13 | 2.88 | 2.43 | 1.84 | 0.65 |
| COL6A3 | collagen, type VI, alpha 3 | 3.13 | 0 | 0 | −0.34 | 1.59 |
| OI4 | collagen, type I, alpha 2 | 0 | 0 | 0 | −2.95 | 0 |
| SEDC | collagen, type II, alpha 1 | 2.35 | 0 | −2.18 | −1.74 | 3.21 |
| DAG1 | dystroglycan 1 (dystrophin-associated glycoprotein 1) | −2.29 | −0.68 | −0.5 | 0 | −0.03 |
| Fndc1 | fibronectin type III domain containing 1 | 4.22 | −2.3 | −2.69 | −0.87 | −2.14 |
| Ibsp | integrin binding sialoprotein | −2.82 | −2.03 | −3.84 | −2.43 | 3.32 |
| ITGA10 | integrin, alpha 10 | 2.86 | 0.93 | 4.74 | 2.05 | 1.85 |
| ITGA2 | integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) | 3.18 | 0.61 | 1.92 | 2.26 | 2.27 |
| ITGA2B | integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | 0.99 | 2.01 | 4.05 | 2.51 | 2.81 |
| ITGA4 | integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) | 1.73 | 1.66 | 2.88 | −0.68 | 0 |
| ITGA8 | integrin, alpha 8 | 0.36 | 1.15 | 3.1 | 0 | 0.86 |
| ITGA9 | integrin, alpha 9 | −3.58 | −2.82 | −2.38 | −1.94 | −0.62 |
| ITGB4 | integrin, beta 4 | 1.31 | 0 | 2.78 | 2.22 | 1.1 |
| LAMA1 | laminin, alpha 1 | 0.38 | 1.27 | 3.41 | 1.28 | 1.09 |
| Lama5 | laminin, alpha 5 | −1.32 | 2.6 | 0.78 | 2.42 | 2.43 |
| LAMB2 | laminin, gamma 1 (formerly LAMB2) | 0.88 | 2.67 | 2.89 | 2.24 | 2.48 |
| LOC131873 | no description | 2.26 | 1.12 | 0.12 | 0.49 | 0.34 |
| Npnt | nephronectin | 3.04 | 0.04 | −0.36 | −2.2 | 0.83 |
| SDC2 | syndecan 2 | 3.71 | 3.82 | 3.01 | 2.91 | 1.95 |
| THBS1 | thrombospondin 1 | −3.07 | −0.85 | 0 | 1.07 | 1.88 |
| THBS2 | thrombospondin 2 | 2.82 | −0.14 | −2.71 | −2.49 | −0.07 |
| Tnn | trophinin | 2.89 | 1.64 | 0.74 | 0 | 0.64 |
| VTN | vitronectin | 0 | 2.25 | 0 | 0 | −1.33 |
The table lists significantly perturbed (activated or repressed) genes at any time among the 5 different time points (0.25 h through 4 h p.i.).